drugset / Trial / NCT00664534

Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast

NCT00664534

Phase 4 Completed 344 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to look at how best to start and then gradually intensify (as needed) the insulin lispro premix regimen in type 2 diabetes patients who consume a light breakfast.

Timeline

Start
2008-04
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Lispro Protein / enzyme biologic Other
Comparator insulin glargine Protein / enzyme biologic Other